A single rule change can turn a compliant merchant into a regulatory target overnight. For businesses selling hemp-derived products, CBD, peptides, and other emerging categories, regulatory uncertainty for hemp and CBD merchants has become a defining challenge. The question is no longer whether rules will change, but how quickly businesses can adapt when they do. […]

The potential rescheduling of cannabis under the Controlled Substances Act (CSA) has been a hotly debated topic for years. With the recent recommendation by the Department of Health and Human Services (HHS) to move cannabis from Schedule I to Schedule III, the question of how this will impact FDA oversight and regulation takes center stage. […]